We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

17 hedge funds and large institutions have $126K invested in Theriva Biologics in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more funds holding

Funds holding: 11 → 17 (+6)

3.65% less ownership

Funds ownership: 6.86% → 3.21% (-3.6%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

40% less capital invested

Capital invested by funds: $210K → $126K (-$83.5K)

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$29.2K
2
VF
Virtu Financial
New York
+$28K
3
TSS
Two Sigma Securities
New York
+$14.5K
4
XT
XTX Topco
Cayman Islands
+$13.9K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.43K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$6.37K
2
Osaic Holdings
Osaic Holdings
Arizona
-$357
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$67

TOVX Hedge Fund Activity: Q2 2025 in Review

17 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2025, worth a combined $126K — down 40% from $210K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TOVX positions and 0 closed out — a net gain of 6 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $29.2K. The largest seller was UBS Group, cutting an estimated $6.37K.

  • 17 institutional investors held Theriva Biologics (TOVX) as of Q2 2025, up from 11 in Q1 2025.
  • Funds reported $126K of Theriva Biologics stock for Q2 2025, down 40% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q2 2025 and 0 closed out, a net change of +6 holders.
  • The largest Theriva Biologics buyer in Q2 2025 was Citadel Advisors, an estimated $29.2K added.
  • The largest Theriva Biologics seller in Q2 2025 was UBS Group, an estimated $6.37K sold.

Based on aggregated 13F filings for Q2 2025.